When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
Install
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)
The odds
82%chance▲ 1
How the odds have moved
Yes: 82% on Nov 3, 82% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 82% | ▲ 1 | 78¢ | 85¢ | $1.18 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, United Therapeutics, Ralinepag
Search ›- Reviewing United Therapeutics (UTHR) and Its PeersPosted by Kim Johansen on Nov 6th, 2026 United Therapeutics (NASDAQ:UTHR – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare United Therapeutics to…
- The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings callUnited Therapeutics (UTHR) Q3 2026 highlights: Our top 5 analyst questions from United Therapeutics’s Q3 earnings call Joseph Thome (TD Cowen) asked about the expected impact of the PH-ILD label removal for YUTREPIA on patient switching…
- United Therapeutics Wins FDA Clearance for Treprostinil-Iloprost Phase 1 TrialUnited Therapeutics secured US Food and Drug Administration clearance for its investigational new drug application for Treprostinil-Iloprost SMI, clearing the way for a phase 1 trial of the... Published on 10/28/2026 at 10:49 am EDT United…
- What Is Drawing Attention To United Therapeutics (UTHR) Today?United Therapeutics (UTHR) just released third quarter 2026 results, reporting revenue of US$832.5 million and diluted earnings per share of US$5.71, alongside the completion of a US$2.0 billion share repurchase authorization. Scan how…
- MannKind anticipates $1B in revenue from United Therapeutics deal from 2027-2030 as it targets Q4 profitabilityMannKind Q3 2026 earnings: Furoscix and Afrezza growth, ReadyFlow conversion, and a Q4 profitability outlook. Earnings Call Insights: MannKind (MNKD) Q3 2026 - "This quarter is about what comes next, moving from delivering catalysts to…
- American billionaire Martine Rothblatt's United Therapeutics posts record $832.5 million third-quarter revenueUnited Therapeutics, the drugmaker founded and run by Martine Rothblatt, reported record third-quarter revenue of $832.5 million, and its shares climbed in early trading. United Therapeutics Corp., the drugmaker founded and run by American…
- What United Therapeutics (UTHR) Said on Its Q3 Earnings CallPosted by Tristan Rich on Nov 4th, 2026 United Therapeutics (NASDAQ:UTHR) reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission…
- Transcript : United Therapeutics Corporation, Q3 2026 Earnings Call, Nov 04, 2026Presentation Operator MessageOperator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2026 Corporate Update. My name is Krista, and I will be your conference operator... Transcript : United Therapeutics…
- Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 9, 2026.marketscreener.com Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 9, 2026. Published on 11/04/2026 at 07:35 am EST - Modified on 11/04/2026 at 08:06 am EST From July 1, 2026 to September 30…
- Earnings Flash (UTHR) United Therapeutics Posts Q3 EPS $5.71, vs. FactSet Est of $6.01... Published on 11/04/2026 at 07:15 am EST United Therapeutics delivers 18th consecutive quarter of topline growth June 17, 2025 at 03:39 am EDT
- United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soarsBiotechnology company United Therapeutics (NASDAQ:UTHR) reported Q3 2026 results topping the market's revenue expectations , with revenue up 4.1% year on year to $832.5 million. Its GAAP profit of $5.71 per share was 5.5% below analysts'…
- United Therapeutics buys out Pfizer royalties linked to lung disease therapyUnited Therapeutics buys out Pfizer royalties (PFE:NYSE) Seeking Alpha United Therapeutics (UTHR) traded higher in premarket trading on Wednesday after the company, alongside its Q3 2026 results, announced the acquisition of Pfizer’s (PFE)…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 5 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions